Synapse

← Steven A. Rosenberg

Papers by Steven A. Rosenberg

Page 8 · newest first

  1. CD4 ⁺ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody productionProceedings of the National Academy of Sciences · 2001
  2. Sequential 5-Aza-2’-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1Journal of Immunotherapy · 2001
  3. A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Nystatin on the Development of Oral Irritation in Patients Receiving High-Dose Intravenous Interleukin-2Journal of Immunotherapy · 2001
  4. Isolation of a New Melanoma Antigen, MART-2, Containing a Mutated Epitope Recognized by Autologous Tumor-Infiltrating T LymphocytesThe Journal of Immunology · 2001
  5. Induction of Tumor-Reactive Cytotoxic T-Lymphocytes Using a Peptide from NY-ESO-1 Modified at the Carboxy-terminus to Enhance HLA-A2.1 Binding Affinity and Stability in SolutionJournal of Immunotherapy · 2001
  6. Patients With Melanoma Metastases at Cutaneous and Subcutaneous Sites Are Highly Susceptible to Interleukin-2–Based TherapyJournal of Immunotherapy · 2001
  7. Expansion and Characterization of T Cells Transduced with a Chimeric Receptor against Ovarian CancerHuman Gene Therapy · 2000
  8. Real-Time Quantitative Polymerase Chain Reaction Assessment of Immune Reactivity in Melanoma Patients After Tumor Peptide VaccinationJNCI Journal of the National Cancer Institute · 2000
  9. Status of Activation of Circulating Vaccine-Elicited CD8+ T CellsThe Journal of Immunology · 2000
  10. Phase 1 Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From the Melanoma-Associated Antigens MART-1 and gp100Journal of Immunotherapy · 2000
  11. Long-Term Survival of Anti-Tumor Lymphocytes Generated by Vaccination of Patients With Melanoma With a Peptide VaccineJournal of Immunotherapy · 2000
  12. Quantitation of T-Cell Receptor Frequencies by Competitive Polymerase Chain Reaction: Dynamics of T-Cell Clonotype Frequencies in an Expanding Tumor-Infiltrating Lymphocyte CultureJournal of Immunotherapy · 2000
  13. Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR MoleculesThe Journal of Immunology · 2000
  14. Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytesInternational Journal of Cancer · 2000
  15. Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytesInternational Journal of Cancer · 2000
  16. Impact of the Number of Treatment Courses on the Clinical Response of Patients Who Receive High-Dose Bolus Interleukin-2Journal of Clinical Oncology · 2000
  17. Decreased Tolerance to Interleukin-2 With Repeated Courses of Therapy in Patients With Metastatic Melanoma or Renal Cell CancerJournal of Immunotherapy · 2000
  18. A Tumor-Infiltrating Lymphocyte from a Melanoma Metastasis with Decreased Expression of Melanoma Differentiation Antigens Recognizes MAGE-12The Journal of Immunology · 2000
  19. Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic MiceThe Journal of Immunology · 2000
  20. Recognition of Shared Melanoma Antigens in Association With Major HLA-A Alleles by Tumor Infiltrating T Lymphocytes From 123 Patients With MelanomaJournal of Immunotherapy · 2000
  21. Functional Analysis of Antigen-Specific T Lymphocytes by Serial Measurement of Gene Expression in Peripheral Blood Mononuclear Cells and Tumor SpecimensThe Journal of Immunology · 1999
  22. Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor RegressionThe Journal of Immunology · 1999
  23. Interleukin-10 Enhances the Therapeutic Effectiveness of a Recombinant Poxvirus-Based Vaccine in an Experimental Murine Tumor ModelJournal of Immunotherapy · 1999
  24. Development and Characterization of Melanoma Cell Lines Established by Fine-Needle Aspiration Biopsy: Advances in the Monitoring of Patients with Metastatic MelanomaCancer Detection and Prevention · 1999
  25. Impact of Cytokine Administration on the Generation of Antitumor Reactivity in Patients with Metastatic Melanoma Receiving a Peptide VaccineThe Journal of Immunology · 1999
  26. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology · 1999
  27. Interleukin-2 Based Immunotherapy for Metastatic Renal Cell Carcinoma With the Kidney in PlaceThe Journal of Urology · 1999
  28. Efficient Transfer of a Tumor Antigen-Reactive TCR to Human Peripheral Blood Lymphocytes Confers Anti-Tumor ReactivityThe Journal of Immunology · 1999
  29. Cloning Genes Encoding MHC Class II-Restricted Antigens: Mutated CDC27 as a Tumor AntigenScience · 1999
  30. Identification of a Novel Major Histocompatibility Complex Class II–restricted Tumor Antigen Resulting from a Chromosomal Rearrangement Recognized by CD4+ T CellsThe Journal of Experimental Medicine · 1999
  31. Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4⁺T lymphocytesProceedings of the National Academy of Sciences · 1999
  32. Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2bJournal of Clinical Oncology · 1999
  33. Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T CellsThe Journal of Experimental Medicine · 1999
  34. Fas-Mediated Suicide of Tumor-Reactive T Cells Following Activation by Specific Tumor: Selective Rescue by Caspase InhibitionThe Journal of Immunology · 1999
  35. Changes in the Fine Specificity of gp100(209–217)-Reactive T Cells in Patients Following Vaccination with a Peptide Modified at an HLA-A2.1 Anchor ResidueThe Journal of Immunology · 1999
  36. High Avidity CTLs for Two Self-Antigens Demonstrate Superior In Vitro and In Vivo Antitumor EfficacyThe Journal of Immunology · 1999
  37. Developing recombinant and synthetic vaccines for the treatment of melanomaCurrent Opinion in Oncology · 1999
  38. Immunizing Patients With Metastatic Melanoma Using Recombinant Adenoviruses Encoding MART-1 or gp100 Melanoma AntigensJNCI Journal of the National Cancer Institute · 1998
  39. Immunizing Patients With Metastatic Melanoma Using Recombinant Adenoviruses Encoding MART-1 or gp100 Melanoma AntigensJNCI Journal of the National Cancer Institute · 1998
  40. Identification of New Melanoma Epitopes on Melanosomal Proteins Recognized by Tumor Infiltrating T Lymphocytes Restricted by HLA-A1, -A2, and -A3 AllelesThe Journal of Immunology · 1998
  41. Apoptotic Death of CD8+ T Lymphocytes After Immunization: Induction of a Suppressive Population of Mac-1+/Gr-1+ CellsThe Journal of Immunology · 1998
  42. A Breast and Melanoma-Shared Tumor Antigen: T Cell Responses to Antigenic Peptides Translated from Different Open Reading FramesThe Journal of Immunology · 1998
  43. Functional Dissociation Between Local and Systemic Immune Response During Anti-Melanoma Peptide VaccinationThe Journal of Immunology · 1998
  44. Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2Annals of Surgery · 1998
  45. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancerCancer · 1998
  46. gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide LigandThe Journal of Experimental Medicine · 1998
  47. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.Journal of Clinical Oncology · 1998
  48. Serum Interleukin-6 Levels in Metastatic Renal Cell Carcinoma Before Treatment With Interleukin-2 Correlates With Paraneoplastic Syndromes but Not Patient SurvivalThe Journal of Urology · 1998
  49. Recognition of an Antigenic Peptide Derived from Tyrosinase-Related Protein-2 by CTL in the Context of HLA-A31 and -A33The Journal of Immunology · 1998
  50. Enhancing Efficacy of Recombinant Anticancer Vaccines With Prime/Boost Regimens That Use Two Different VectorsJNCI Journal of the National Cancer Institute · 1997